CMS Bladder Stimulators (Pacemakers) Coverage Policy — NCD 243 Updated for 2026

The Centers for Medicare & Medicaid Services (CMS) has issued a modified version of National Coverage Determination (NCD) 243, governing Medicare coverage of bladder stimulators — devices also known as bladder pacemakers. This update reaffirms CMS's long-standing non-coverage position on bladder wall stimulators, rectal electrical stimulators, and spinal cord electrical stimulators used for bladder emptying. Billing teams and RCM directors submitting claims for these procedures under Medicare should treat this policy as an active denial risk and review their claim workflows accordingly.

What CMS NCD 243 Covers — and What It Doesn't

CMS classifies bladder stimulators under the Prosthetic Devices benefit category. Despite that classification, this NCD draws a hard line: none of these devices qualify as reasonable and necessary under Medicare, which means no program payment may be made — either for the devices themselves or for the implantation procedures.

This is a blanket non-coverage determination. There are no tiered criteria, no diagnosis-specific exceptions, and no pathway to prior authorization approval that would unlock reimbursement. The policy language is unambiguous — these services are excluded from Medicare payment in all circumstances.

Which Devices Are Explicitly Excluded Under CMS NCD 243

The policy identifies three specific device types, all used to induce urinary bladder emptying through electrical stimulation:

• Bladder wall stimulators — electrodes implanted directly into the wall of the bladder
• Rectal electrical stimulators — devices that use rectal cones to deliver electrical current
• Spinal cord electrical stimulators — electrodes placed at the spinal cord level to control bladder function

It's worth noting that spinal cord stimulators used for pain management are governed by a separate NCD and have their own coverage criteria. NCD 243 is specifically scoped to spinal cord stimulator use for bladder emptying — a critical distinction for urology and neurosurgery billing teams who may submit spinal cord stimulator claims across multiple indications.

Why CMS Considers Bladder Stimulators Not Reasonable and Necessary

The policy summary gives billing teams important context for appeals and patient conversations. CMS's non-coverage rationale rests on two core concerns:

1. Unresolved safety issues. CMS cites ongoing problems with infection risk, device erosion, electrode placement complications, and material selection. These aren't theoretical concerns — they reflect a body of clinical evidence that has not, in CMS's determination, satisfactorily established that the benefit outweighs the harm.

2. Pain and patient tolerability. The policy explicitly notes that some facilities that previously used electronic bladder emptying methods have discontinued them because of the pain patients experienced. This speaks directly to the "reasonable and necessary" standard — a service must be both clinically appropriate and tolerable for the patient population.

These factors combine to disqualify bladder stimulators from Medicare coverage under any current medical necessity framework. There is no documentation pathway or clinical criteria checklist that changes this outcome.

Prior Authorization Requirements Under NCD 243

NCD 243 does not include a prior authorization process for these devices — because there is nothing to authorize. The non-coverage determination preempts any prior auth workflow. Submitting a prior auth request for a Medicare bladder stimulator implant would not result in an approval, and proceeding to implant would not result in reimbursement.

For practices that have historically used prior auth as a utilization management step, this distinction matters: the absence of a PA pathway here isn't an oversight — it reflects the absolute nature of the exclusion.

CMS Bladder Stimulator Policy and the Affected Patient Population

The patients most likely to be considered for these devices — those with neurogenic bladder, spinal cord injury, or refractory urinary retention — are often Medicare beneficiaries. That overlap makes NCD 243 particularly consequential for urology and physiatry practices serving an older or disabled population.

Practices should ensure that any patient conversations about bladder stimulator options include clear disclosure that Medicare will not cover these devices. An Advance Beneficiary Notice of Noncoverage (ABN) is required when providing a non-covered service to a Medicare patient who may otherwise expect coverage — though in this case, even an ABN does not create a path to Medicare reimbursement.

Patients seeking this treatment will need to pursue it through private pay, supplemental insurance, or clinical trial enrollment, depending on their situation.

Affected Codes

The policy does not list specific CPT or HCPCS codes. Per the official CMS document for NCD 243, no procedure codes are enumerated within the policy itself. Billing teams should consult their Medicare Administrative Contractor (MAC) for claims processing guidance on how to handle any submitted claims for these services and whether specific codes trigger automatic denial under this NCD.

There are no covered codes under this policy. All bladder stimulator devices and implantation procedures described in NCD 243 are excluded from Medicare payment.

Related ICD-10 diagnoses that might be associated with bladder stimulator consideration — such as neurogenic bladder or urinary retention — do not alter coverage status. Diagnosis coding does not create an exception to this NCD.

What Your Billing Team Should Do